Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor–binding protein 3?

Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor–binding protein 3?

Hanna A Zielinska,1 Amit Bahl,2 Jeff MP Holly,1 Claire M Perks1 1IGFs and Metabolic Endocrinology Group, School of Clinical Sciences, University of Bristol, Learning and Research Building, Southmead Hospital, Bristol, UK; 2Department of Clinical Oncology, Bristol Haematology and Oncology Centre, Un...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zielinska HA, Bahl A, Holly JMP, Perks CM
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/902c945b429a42748d1e1bb6f60e74c9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:902c945b429a42748d1e1bb6f60e74c9
record_format dspace
spelling oai:doaj.org-article:902c945b429a42748d1e1bb6f60e74c92021-12-02T01:45:43ZEpithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor–binding protein 3?1179-1314https://doaj.org/article/902c945b429a42748d1e1bb6f60e74c92015-01-01T00:00:00Zhttp://www.dovepress.com/epithelial-to-mesenchymal-transition-in-breast-cancer-a-role-for-insul-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314 Hanna A Zielinska,1 Amit Bahl,2 Jeff MP Holly,1 Claire M Perks1 1IGFs and Metabolic Endocrinology Group, School of Clinical Sciences, University of Bristol, Learning and Research Building, Southmead Hospital, Bristol, UK; 2Department of Clinical Oncology, Bristol Haematology and Oncology Centre, University Hospitals Bristol, Bristol, UK Abstract: Evidence indicates that for most human cancers the problem is not that gene mutations occur but is more dependent upon how the body deals with damaged cells. It has been estimated that only about 1% of human cancers can be accounted for by unmistakable hereditary cancer syndromes, only up to 5% can be accounted for due to high-penetrance, single-gene mutations, and in total only 5%–15% of all cancers may have a major genetic component. The predominant contribution to the causation of most sporadic cancers is considered to be environmental factors contributing between 58% and 82% toward different cancers. A nutritionally poor lifestyle is associated with increased risk of many cancers, including those of the breast. As nutrition, energy balance, macronutrient composition of the diet, and physical activity levels are major determinants of insulin-like growth factor (IGF-I) bioactivity, it has been proposed that, at least in part, these increases in cancer risk and progression may be mediated by alterations in the IGF axis, related to nutritional lifestyle. Localized breast cancer is a manageable disease, and death from breast cancer predominantly occurs due to the development of metastatic disease as treatment becomes more complicated with poorer outcomes. In recent years, epithelial-to-mesenchymal transition has emerged as an important contributor to breast cancer progression and malignant transformation resulting in tumor cells with increased potential for migration and invasion. Furthermore, accumulating evidence suggests a strong link between components of the IGF pathway, epithelial-to-mesenchymal transition, and breast cancer mortality. Here, we highlight some recent studies highlighting the relationship between IGFs, IGF-binding protein 3, and epithelial-to-mesenchymal transition. Keywords: IGF-I, IGFBP-3, EMT, breast cancerZielinska HABahl AHolly JMPPerks CMDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 9-19 (2015)
institution DOAJ
collection DOAJ
language EN
topic Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Zielinska HA
Bahl A
Holly JMP
Perks CM
Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor–binding protein 3?
description Hanna A Zielinska,1 Amit Bahl,2 Jeff MP Holly,1 Claire M Perks1 1IGFs and Metabolic Endocrinology Group, School of Clinical Sciences, University of Bristol, Learning and Research Building, Southmead Hospital, Bristol, UK; 2Department of Clinical Oncology, Bristol Haematology and Oncology Centre, University Hospitals Bristol, Bristol, UK Abstract: Evidence indicates that for most human cancers the problem is not that gene mutations occur but is more dependent upon how the body deals with damaged cells. It has been estimated that only about 1% of human cancers can be accounted for by unmistakable hereditary cancer syndromes, only up to 5% can be accounted for due to high-penetrance, single-gene mutations, and in total only 5%–15% of all cancers may have a major genetic component. The predominant contribution to the causation of most sporadic cancers is considered to be environmental factors contributing between 58% and 82% toward different cancers. A nutritionally poor lifestyle is associated with increased risk of many cancers, including those of the breast. As nutrition, energy balance, macronutrient composition of the diet, and physical activity levels are major determinants of insulin-like growth factor (IGF-I) bioactivity, it has been proposed that, at least in part, these increases in cancer risk and progression may be mediated by alterations in the IGF axis, related to nutritional lifestyle. Localized breast cancer is a manageable disease, and death from breast cancer predominantly occurs due to the development of metastatic disease as treatment becomes more complicated with poorer outcomes. In recent years, epithelial-to-mesenchymal transition has emerged as an important contributor to breast cancer progression and malignant transformation resulting in tumor cells with increased potential for migration and invasion. Furthermore, accumulating evidence suggests a strong link between components of the IGF pathway, epithelial-to-mesenchymal transition, and breast cancer mortality. Here, we highlight some recent studies highlighting the relationship between IGFs, IGF-binding protein 3, and epithelial-to-mesenchymal transition. Keywords: IGF-I, IGFBP-3, EMT, breast cancer
format article
author Zielinska HA
Bahl A
Holly JMP
Perks CM
author_facet Zielinska HA
Bahl A
Holly JMP
Perks CM
author_sort Zielinska HA
title Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor–binding protein 3?
title_short Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor–binding protein 3?
title_full Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor–binding protein 3?
title_fullStr Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor–binding protein 3?
title_full_unstemmed Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor–binding protein 3?
title_sort epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor i and insulin-like growth factor–binding protein 3?
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/902c945b429a42748d1e1bb6f60e74c9
work_keys_str_mv AT zielinskaha epithelialtomesenchymaltransitioninbreastcanceraroleforinsulinlikegrowthfactoriandinsulinlikegrowthfactorndashbindingprotein3
AT bahla epithelialtomesenchymaltransitioninbreastcanceraroleforinsulinlikegrowthfactoriandinsulinlikegrowthfactorndashbindingprotein3
AT hollyjmp epithelialtomesenchymaltransitioninbreastcanceraroleforinsulinlikegrowthfactoriandinsulinlikegrowthfactorndashbindingprotein3
AT perkscm epithelialtomesenchymaltransitioninbreastcanceraroleforinsulinlikegrowthfactoriandinsulinlikegrowthfactorndashbindingprotein3
_version_ 1718402906442432512

Ejemplares similares